Rafarma Pharmaceuticals is trading at 0.087 as of the 29th of November 2024, a 4.4 percent decrease since the beginning of the trading day. The stock's open price was 0.091. Rafarma Pharmaceuticals has more than 60 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Rafarma Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of May 2023 and ending today, the 29th of November 2024. Click here to learn more.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.. More on Rafarma Pharmaceuticals
Rafarma Pharmaceuticals [RAFA] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 110.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Rafarma Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Rafarma Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Rafarma Pharmaceuticals conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry.
Rafarma Pharmaceuticals generates negative cash flow from operations
Check Rafarma Pharmaceuticals Probability Of Bankruptcy
Our tools can tell you how much better you can do entering a position in Rafarma Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Risk-Return Analysis Now
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Other Information on Investing in Rafarma Pink Sheet
Rafarma Pharmaceuticals financial ratios help investors to determine whether Rafarma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rafarma with respect to the benefits of owning Rafarma Pharmaceuticals security.